Clinical trials: Neoplasm, Oral
Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer
This phase III trial tests if gabapentin can prevent the need for opiate pain medication for mouth sores (oral mucositis) in patients undergoing treatment with chemotherapy and radiation for squamous cell carcinoma of the head…
- Conditions
- Head and Neck Squamous Cell Carcinoma, Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8, Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8
- Trial name
- HOPE (NCT06992427)
- Testing
- Gabapentin, Chemotheraphy, Radiation Therapy
- Where
- 212 sites in United States
- Volunteers
- 228 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Skin Cancer, Skin Cancer Face
Nasal Iodine Swab Versus Oral Antibiotic to Prevent Surgical Site Infection After Undergoing Mohs Micrographic Surgery
The purpose of this study is to compare surgical site infection rates for patients treated with Mohs micrographic surgery after bilateral nasal swab with povidone iodine versus standard treatment including the use of a…
- Conditions
- Skin Cancer, Skin Cancer Face, Malignant Cutaneous Adnexal Neoplasm
- Trial name
- NCT06207786
- Testing
- Povidone-Iodine Swabs, Staphylococcus nasal swab, Antibiotic
- Sponsor
- Mayo Clinic
Neoplasm
Modern Hybrid Imaging in Patients With OSCC
Prospective diagnostic study to determine the diagnostic accuracy of preoperative 18F--fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) in detecting local tumor extent, cervical lymph node…
- Trial name
- PETOSCC (NCT04280159)
- Where
- Germany
- Volunteers
- 265 people
- Sponsor
- Wuerzburg University Hospital
Leukemia, Leukemia, Myeloid
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
Study BH-30236-01 is a first-in-human (FIH), Phase 1/1b, open-label, dose escalation and expansion study in participants with relapsed/refractory acute myelogenous leukemia (R/R AML) or higher-risk myelodysplastic syndrome…
- Conditions
- Leukemia, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Preleukemia
- Trial name
- NCT06501196
- Testing
- BH-30236, Venetoclax
- Where
- 13 sites in United States
- Volunteers
- 170 people
- Sponsor
- BlossomHill Therapeutics
Breast Cancer
Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)
This is a prospective, open-lable Phase II clinical trial (ORCHID study) evaluating the effectiveness and safety of oral vinorelbine or capecitabine combined with trastuzumab as adjuvant treatment for patients with lymph node…
- Trial name
- ORCHID (NCT04296162)
- Testing
- Vinorelbine, Capecitabine, Trastuzumab
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Fudan University
Skin Cancer, Mucosal Neoplasm of Oral Cavity
Retreatment With Intratumoral Diffusing Alpha Radiation Emitters
A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia
- Conditions
- Skin Cancer, Mucosal Neoplasm of Oral Cavity, Soft Tissue Neoplasm
- Trial name
- NCT04540588
- Testing
- Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
- Where
- Israel
- Volunteers
- 2 people
- Sponsor
- Alpha Tau Medical LTD.
Solid Tumours
A Phase I Topotecan Study in Subjects With Cancer and Impaired Renal Function
To determine the effect of renal impairment and prior platinum-based chemotherapy on the safety and blood levels of topotecan administered orally
- Trial name
- NCT00483860
- Testing
- Topotecan
- Where
- 6 sites in United States, Netherlands and 1 more
- Volunteers
- 59 people
- Sponsor
- GlaxoSmithKline
Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
In this clinical trial, the safety, tolerability, and preliminary antitumor activity of ziftomenib in combination with imatinib will be evaluated in adults with gastrointestinal stromal tumors (GIST) who have been treated…
- Conditions
- Gastrointestinal Stromal Tumor (GIST), Gastrointestinal Stromal Cancer, Gastrointestinal Stromal Neoplasm, Gastrointestinal Stromal Tumor, Malignant
- Trial name
- NCT06655246
- Testing
- ziftomenib, imatinib mesylate
- Where
- 32 sites in United States
- Volunteers
- 135 people
- Sponsor
- Kura Oncology, Inc.
Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Compartmentalized Postoperative Radiotherapy in Head and Neck Cancer
COMPORT is a multicenter phase II clinical trial evaluating a personalized approach to postoperative radiotherapy in patients with head and neck squamous cell carcinoma (HNSCC).
- Conditions
- Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- COMPORT (NCT07058805)
- Testing
- Compartmentalized Postoperative Radiotherapy
- Where
- 3 sites in Switzerland
- Volunteers
- 50 people
- Sponsor
- Olgun Elicin
Head and Neck Cancer
Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer
The investigators are conducting research about oral health and saliva to find out more about the impact of radiation therapy on the oral health of patients.
- Trial name
- NCT01663246
- Testing
- Saliva Sample
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Michigan Rogel Cancer Center
Oral Cancer
Validation of Salivary Proteomic Biomarkers for Early Detection of Oral Cancer in Egyptian Population
The present investigation was conducted on 100 individuals allocated into four groups; 25 healthy controls, 25 patients having OPMDs with dysplasia; 25 patients having OPMDs without dysplasia, and 25 oral cancer patients.
- Trial name
- NCT06471270
- Testing
- histologic evaluation, biochemical analysis, clinical examination
- Where
- Egypt
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- British University In Egypt
Oral Lichen Planus, Oral Squamous Cell Carcinoma
Molecular Mechanisms of the Development of Precancerous and Cancerous Lesions of the Oral Cavity
The aim of this study was to examine molecular alterations on the protein level in lesions of oral lichen planus (OLP), oral squamous cell carcinoma (OSCC) and healthy mucosa.
- Trial name
- NCT03026361
- Testing
- global proteomic profiling
- Where
- Croatia
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of Zagreb
Breast Cancer
Vinorelbine and Celecoxib in Treating Women With Relapsed or Metastatic Breast Cancer
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. Drugs used in chemotherapy, such as vinorelbine, work in different ways to stop tumor cells from dividing so they…
- Trial name
- NCT00075673
- Testing
- celecoxib, vinorelbine ditartrate
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Case Comprehensive Cancer Center
Advanced Refractory Solid Tumors
An Extension Study for T-1101 (Tosylate) to Treat Advanced Refractory Solid Tumors
T-1101 is a novel anti-cancer agent being developed by Taivex Therapeutics Corporation, and is being studied in a phase I dose escalation trial, protocol TAI-001.
- Trial name
- NCT03349073
- Testing
- T-1101 (Tosylate)
- Where
- 4 sites in Taiwan
- Volunteers
- 3 people
- Sponsor
- Taivex Therapeutics Corporation
Acute Myeloid Leukemia
A Post-Marketing Surveillance Study to Assess the Safety of Oral Azacitidine Maintenance Therapy in Korean Patients With Acute Myeloid Leukemia
The purpose of this observational study is to assess the real-world safety of maintenance therapy with oral azacitidine in Korean participants with acute myeloid leukemia (AML) who achieved first complete remission (CR) or…
- Trial name
- NCT06073769
- Testing
- Oral azacitidine
- Where
- 2 sites in South Korea
- Volunteers
- 154 people
- Sponsor
- Bristol-Myers Squibb
Mouth Diseases
Optical Sensor for Photodynamic Detection of Oral Pathology
Overall objective of this work is to develop better ways of detecting, diagnosing and measuring oral diseases and structures using light and optical approaches.
- Trial name
- NCT00540774
- Testing
- detection of oral pathology
- Where
- United States
- Volunteers
- 1,004 people, healthy volunteers welcome
- Sponsor
- University of California, Irvine
Advanced Cancer
A Study of LY2228820 in Participants With Advanced Cancer
The objective of this study is to determine a safe dose of LY2228820 that may be given to participants with advanced cancer. Part A of this study will consist of dose escalation, and Part B will consist of dose confirmation.
- Trial name
- NCT01393990
- Testing
- LY2228820, Midazolam, Tamoxifen
- Where
- 2 sites in United States
- Volunteers
- 89 people
- Sponsor
- Eli Lilly and Company
Oral Mucositis, Stomatitis
A Phase II Controlled Trial of Velafermin for Prevention of Oral Mucositis
CG53135-05 (velafermin), a recombinant human fibroblast growth factor-20 (rhFGF-20) protein, is under investigation for the prevention of oral mucositis.
- Trial name
- NCT00323518
- Testing
- velafermin
- Where
- 33 sites in United States
- Volunteers
- 390 people
- Sponsor
- CuraGen Corporation
Breast Cancer
The Effect of Oral Administration of Hesperidin and Diosmin in Reducing Paclitaxel-induced Peripheral Neuropathy in Breast Cancer Patients
The aim of this study is evaluation of the potential neuroprotective effect of oral hesperidin and diosmin in reducing paclitaxel- induced peripheral neuropathy in the treatment of breast cancer patients.
- Trial name
- NCT06811220
- Testing
- Hespiridin and Diosmin
- Volunteers
- 140 people
- Sponsor
- Alexandria University
Advanced Solid Tumors
LBH589 Oral in Combination With Carboplatin and Paclitaxel in Advanced Solid Tumors
The purpose of this study is to determine the Maximum Tolerated Dose (MTD) of Panobinostat (LBH589) when administered in combination with Carboplatin and Paclitaxel in patients with advanced solid malignancies and to identify the…
- Trial name
- NCT01159418
- Testing
- Panobinostat (LBH589), Carboplatin and Paclitaxel
- Where
- 3 sites in Switzerland
- Volunteers
- 36 people
- Sponsor
- Southern Europe New Drug Organization
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.